JP2016529232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529232A5 JP2016529232A5 JP2016526507A JP2016526507A JP2016529232A5 JP 2016529232 A5 JP2016529232 A5 JP 2016529232A5 JP 2016526507 A JP2016526507 A JP 2016526507A JP 2016526507 A JP2016526507 A JP 2016526507A JP 2016529232 A5 JP2016529232 A5 JP 2016529232A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- targeting moiety
- composition according
- antagonist
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306045.9 | 2013-07-19 | ||
| EP13306045 | 2013-07-19 | ||
| PCT/EP2014/063976 WO2015007520A1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529232A JP2016529232A (ja) | 2016-09-23 |
| JP2016529232A5 true JP2016529232A5 (enExample) | 2017-08-10 |
| JP6475712B2 JP6475712B2 (ja) | 2019-02-27 |
Family
ID=48874233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526507A Active JP6475712B2 (ja) | 2013-07-19 | 2014-07-01 | サイトカインアンタゴニストの標的化 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9732135B2 (enExample) |
| EP (1) | EP3022230B1 (enExample) |
| JP (1) | JP6475712B2 (enExample) |
| KR (1) | KR102305608B1 (enExample) |
| CN (1) | CN105658669A (enExample) |
| AU (1) | AU2014292355B2 (enExample) |
| CA (1) | CA2918119C (enExample) |
| IL (1) | IL243459B (enExample) |
| MX (1) | MX375426B (enExample) |
| SG (2) | SG10202010429YA (enExample) |
| WO (1) | WO2015007520A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| JP6475712B2 (ja) * | 2013-07-19 | 2019-02-27 | ヴィブ ブイゼットダブリュー | サイトカインアンタゴニストの標的化 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| US20190077871A1 (en) * | 2016-03-07 | 2019-03-14 | Vib Vzm | Cd20 binding agents and uses thereof |
| US11753463B2 (en) * | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| EP3529264B1 (en) | 2016-10-24 | 2022-03-09 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| KR102659140B1 (ko) | 2017-08-09 | 2024-04-19 | 오리오니스 바이오사이언시스 인코포레이티드 | Clec9a 결합제 및 그의 용도 |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| CA3069930A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| KR102877915B1 (ko) | 2018-02-05 | 2025-10-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| KR20220012227A (ko) | 2019-03-28 | 2022-02-03 | 오리오니스 바이오사이언시즈 인코포레이티드 | Clec9a-기반 키메라 단백질 복합체 |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| WO2022200525A1 (en) | 2021-03-26 | 2022-09-29 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| CN120051483A (zh) | 2022-08-18 | 2025-05-27 | 再生元制药公司 | 干扰素前蛋白及其用途 |
| WO2024238415A1 (en) | 2023-05-12 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE103932T1 (de) | 1989-08-22 | 1994-04-15 | Immunex Corp | Fusionsprotein bestehend aus gm-csf und il-3. |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| CA2252557A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of interleukin-15 |
| ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| CN101304758B (zh) | 2005-06-29 | 2013-08-21 | 维兹曼科学研究所耶达研究与发展有限公司 | 重组干扰素α2（IFNα2）突变体 |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| CN108948177B (zh) * | 2007-05-11 | 2022-04-22 | 阿尔托生物科学有限公司 | 融合分子与il-15变异体 |
| JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| EP2853267B1 (en) | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US20110224407A1 (en) * | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| WO2011029870A1 (en) | 2009-09-10 | 2011-03-17 | Cytos Biotechnology Ag | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| EA034989B1 (ru) * | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| WO2013134138A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| JP6475712B2 (ja) * | 2013-07-19 | 2019-02-27 | ヴィブ ブイゼットダブリュー | サイトカインアンタゴニストの標的化 |
-
2014
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/ja active Active
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 MX MX2016000721A patent/MX375426B/es active IP Right Grant
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/ko active Active
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en not_active Ceased
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/zh active Pending
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529232A5 (enExample) | ||
| CY1124944T1 (el) | Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων | |
| PL3882275T3 (pl) | Przeciwciało dwufunkcyjne anty-pd-1 i anty-vegfa, kompozycja farmaceutyczna i zastosowanie tych przeciwciał | |
| JP2016527221A5 (enExample) | ||
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| SA522432917B1 (ar) | ميوتينات إنترليوكين-21 وطرق العلاج | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| WO2018226578A8 (en) | Nectin-4 binding proteins and methods of use thereof | |
| JP2016525516A5 (enExample) | ||
| PH12018501611A1 (en) | Antigen binding proteins thant bind pd-l1 | |
| PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| PH12018501080A1 (en) | Pd1 and/or lag3 binders | |
| MX2021006389A (es) | Anticuerpo cd3 y uso farmaceutico del mismo. | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
| HRP20221284T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
| WO2014055897A3 (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| MX375426B (es) | Direccionamiento de antagonistas de citocinas. | |
| JP2015535691A5 (enExample) | ||
| JOP20140049B1 (ar) | أجسام مضادة ترتبط بـ il-23 | |
| EA201892440A1 (ru) | Антитела к tl1a и их применения | |
| JP2018514576A5 (enExample) | ||
| JP2017014254A5 (enExample) | ||
| PH12018500131A1 (en) | Il22 immunoconjugates |